XML 80 R40.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2

Collaboration Agreements (Ipsen Collaboration, Narrative) (Details)	3 Months Ended								12 Months Ended
	Jan. 03, 2020 USD ($)	Sep. 27, 2019 USD ($)	Jun. 28, 2019 USD ($)	Mar. 29, 2019 USD ($)	Dec. 28, 2018 USD ($)	Sep. 29, 2018 USD ($)	Jun. 29, 2018 USD ($)	Mar. 31, 2018 USD ($)	Jan. 03, 2020 USD ($)	Jan. 03, 2020 CAD ($)	Dec. 28, 2018 USD ($)	Dec. 29, 2017 USD ($)	Dec. 30, 2016 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments earned	$ 15,100,000	$ 50,600,000	$ 20,400,000	$ 10,000,000.0	$ 29,600,000	$ 42,600,000	$ 25,800,000	$ 66,500,000
Remaining performance obligation	63,100,000								$ 63,100,000
Collaborative Arrangement with GlaxoSmithKline
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration agreement percent of royalty on net sale									3.00%	3.00%
Collaborative arrangement with Ipsen
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaboration period to achieve specified levels of commercial performance									10 years	10 years
Upfront payments													$ 210,000,000.0
Milestone payments earned to date	330,000,000.0								$ 330,000,000.0
Milestone payments earned									55,000,000.0		$ 140,000,000.0
Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement	79,000,000.0								79,000,000.0
Maximum amount eligible for commercial milestones under collaborations agreement	470,400,000								$ 470,400,000
Research and development arrangement performed for others, reimbursement for costs incurred, percent									35.00%	35.00%
Net contract liability	152,800,000				182,900,000				$ 152,800,000		182,900,000	$ 69,800,000
Remaining performance obligation	45,000,000.0								$ 45,000,000.0
Collaborative arrangement with Ipsen | Final tier
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty tier										$ 30,000,000.0
Collaborative arrangement with Ipsen | Minimum | Final tier
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percent of royalty on net sale									22.00%	22.00%
Collaborative arrangement with Ipsen | Maximum | Final tier
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percent of royalty on net sale									26.00%	26.00%
Collaborative arrangement with Takeda
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payments												50,000,000.0
Milestone payments earned to date	26,000,000.0								$ 26,000,000.0
Milestone payments earned									16,000,000.0		10,000,000.0
Eligible payment from collaboration for development and regulatory milestone achievement under collaborations agreement	10,000,000.0								10,000,000.0
Maximum amount eligible for commercial milestones under collaborations agreement	155,000,000.0								155,000,000.0
Net contract liability	24,600,000				$ 18,000,000.0				24,600,000		$ 18,000,000.0	$ 14,800,000
Remaining performance obligation	$ 18,100,000								18,100,000
Collaborative arrangement with Takeda | Initial
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty tier									$ 300,000,000.0
Collaborative arrangement with Takeda | Minimum | Final tier
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percent of royalty on net sale									20.00%	20.00%
Collaborative arrangement with Takeda | Minimum | Initial
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percent of royalty on net sale									15.00%	15.00%
Collaborative arrangement with Takeda | Maximum | Final tier
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percent of royalty on net sale									30.00%	30.00%
Collaborative arrangement with Takeda | Maximum | Initial
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percent of royalty on net sale									24.00%	24.00%

X

- Definition

Collaboration Agreement, Percent Of Royalty On Net Sale

+ References

No definition available.

+ Details

Name:	exel_CollaborationAgreementPercentOfRoyaltyOnNetSale
Namespace Prefix:	exel_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Collaborative Arrangement, Achievement Levels of Commercial Performance, Period

+ References

No definition available.

+ Details

Name:	exel_CollaborativeArrangementAchievementLevelsofCommercialPerformancePeriod
Namespace Prefix:	exel_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Eligible Payment From Collaboration For Development And Regulatory Milestone Achievement Under Collaborations Agreement

+ References

No definition available.

+ Details

Name:	exel_EligiblePaymentFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievementUnderCollaborationsAgreement
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Maximum amount eligible for commercial milestones under collaborations agreement.

+ References

No definition available.

+ Details

Name:	exel_MaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Milestone Payments Earned

+ References

No definition available.

+ Details

Name:	exel_MilestonePaymentsEarned
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Milestone Payments Earned To Date

+ References

No definition available.

+ Details

Name:	exel_MilestonePaymentsEarnedToDate
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Percent of royalty on net sale.

+ References

No definition available.

+ Details

Name:	exel_PercentOfRoyaltyOnNetSale
Namespace Prefix:	exel_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Research and Development Arrangement Performed for Others, Reimbursement for Costs Incurred, Percent

+ References

No definition available.

+ Details

Name:	exel_ResearchandDevelopmentArrangementPerformedforOthersReimbursementforCostsIncurredPercent
Namespace Prefix:	exel_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Royalty Tier

+ References

No definition available.

+ Details

Name:	exel_RoyaltyTier
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Upfront Payment(s)

+ References

No definition available.

+ Details

Name:	exel_UpfrontPayments
Namespace Prefix:	exel_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Amount of transaction price allocated to performance obligation that has not been recognized as revenue.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Details

Name:	srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	exel_RoyaltyTierAxis=exel_FinalTierMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	exel_RoyaltyTierAxis=exel_InitialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: